Entero Healthcare Solutions Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Entero Healthcare Solutions Ltd trades at ₹1,417, in a confirmed uptrend and 15 weeks into that stage. That is +19.3% against its own 200-day average. It sits at 100% of a 52-week range of ₹953 to ₹1,417. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.

Today the stock is in a confirmed uptrend — week 15 of stage 2, confirmed. At ₹1,417 it trades +19.3% versus its 200-day average and sits at 100% of its 52-week range (₹953–₹1,417).

Against the market, two honest reads. Cumulative: over the last 2.5 years the stock moved +23% while the NIFTY 500 moved +17% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Entero Healthcare Solutions Ltd's story is not scored yet against the markers our research file set on 14 June 2026. Where it sits in its own cycle: MID_CONTRACTION. Still open: FY27 5% EBITDA margin guidance requires +100bps expansion on FY26's 4%; management's prior Q3 FY26 miss (4.0% vs guided 4.5-4.75%) means the next miss would materially damage re-rating thesis.

Our read, 14 June 2026. FY26 fully delivered — 31.5% revenue growth, EBITDA margin inflected to 4%, OCF Rs96 Cr; the re-rating thesis now pivots to FY27's 5% EBITDA margin promise with Medtech at 15% of revenue.

From the numbers. PE compressed from 82.15x peak (Jun 2024) to 41.4x current — 49.6% compression while earnings accelerated 94.67% over 8 quarters. PE now at 25th percentile vs 10-year median of 54.8x. The compression is earnings-driven…

From the price. Price stage 2, week 15 — above its 200-day line, relative strength rising.

From the research. FY26 fully delivered — 31.5% revenue growth, EBITDA margin inflected to 4%, OCF Rs96 Cr; the re-rating thesis now pivots to FY27's 5% EBITDA margin promise with Medtech at 15% of revenue.

🚨 Where they disagree. PE compressed from 82.15x peak (Jun 2024) to 41.4x current — 49.6% compression while earnings accelerated 94.67% over 8 quarters. PE now at 25th percentile vs 10-year median of 54.8x. The compression is earnings-driven (EARNINGS_DRIVEN decomposition from pe_pb_expansion_snapshots) — the market is growing into the multiple rather than re-rating. FY26 delivery (ROCE 14.6%, ROE 12.5%, OCF positive) removes the execution uncertainty that drove the de-rating from 82x. The setup is: PE at 25th percentile with forward earnings inflecting upward and EBITDA margin expansion confirmed — a STRONG_OPPORTUNITY matrix entry if FY27 5% margin guidance is met. FII selling (661bps over 5 quarters) is the…

What is proven. FY26 fully delivered — 31.5% revenue growth, EBITDA margin inflected to 4%, OCF Rs96 Cr; the re-rating thesis now pivots to FY27's 5% EBITDA margin promise with Medtech at 15% of revenue.

What is not proven yet. FY27 5% EBITDA margin guidance requires +100bps expansion on FY26's 4%; management's prior Q3 FY26 miss (4.0% vs guided 4.5-4.75%) means the next miss would materially damage re-rating thesis.

Layer 1 read, 19 July 2026 — KEEP. Early-innings margin inflection at the 6th percentile of its own valuation — earnings-driven, not a re-rating. Entero's PE compressed ~50% from its 82x peak to the 6th percentile of its own history on an explicitly EARNINGS_DRIVEN, near-trough basis, while EBITDA margin inflected +67bps to 4% and quarterly PAT ran 21 to 45 Cr with ROCE up 10.7 to 14.6%. The one open question is cash conversion — historically accrual-heavy — but FY26 was the first positive-OCF year in company history, so it's a milestone to watch, not a broken thesis.

What would change Layer 1’s mind. Q1 FY27 EBITDA margin failing to hold >=4.5% (M1, the second test after the prior Q3 miss) OR FY27 OCF falling short of Rs 200 Cr / 50% conversion (M3) — either would show the margin inflection and the just-turned cash engine were a one-year blip, breaking the compressed-multiple-plus-earnings thesis.

Layer 2 read, 19 July 2026 — ADVANCE. Textbook compressed-multiple-with-rising-EPS setup, but the cash-conversion question is still open — advance and let L3 test durability. Entero's PE sits at the 6th percentile of its own history after a -48% de-rating while earnings inflect (rev +31.5%, PAT 21->45Cr, ROCE 10.7->14.6%) — the winner archetype, not the value trap. FY26 delivered the first positive operating cash flow in company history (Rs96.2Cr), directly answering the long-standing cash-burn worry that a Tier-1 channel flagged bearishly. The open question is whether that OCF inflection is durable or acquisition-timing noise, and whether FY27's 5% margin lands — an L3 investigation, not a reason to reject a P2 with two bullish rel-1.0 confirms and promoter buying.

What would change Layer 2’s mind. If L3 finds the FY26 positive OCF was an acquisition-timing/window-dressing artifact and Q1-Q2 FY27 OCF turns negative again, OR the FY27 5% EBITDA margin misses (the second test after the prior Q3 miss, risk R1) — that would confirm the cash-burning-roll-up thesis and flip this ADVANCE to DROP.

Layer 3 read, 19 July 2026 — DEPLOY. The 'cash-burning roll-up' bear call was right for 5 years — and Entero just reversed it: FY26 is the first positive-OCF year.

What would change Layer 3’s mind. FY27 H1 OCF slipping back negative (the NWC compression proving to be a one-year timing release, not structural), OR a second consecutive EBITDA-margin miss versus the 5% FY27 guide — either would escalate the roll-up cash-burn risk back to HIGH and flip DEPLOY->DROP.

The test written in advance. FY27 Margin Delivery — Second Test After Prior Q3 Miss — FY27 Margin Delivery — Second Test After Prior Q3 Miss Q1 FY27 EBITDA margin (must be ≥4.5% to confirm FY27 trajectory toward 5%) by the next result.

The test written in advance. Management Consistency — Two New Flags in May 2026 Call — Management Consistency — Two New Flags in May 2026 Call Q1 FY27 concall: are risks and misses disclosed proactively or only explained retroactively? by the next result.

The test written in advance. FII Institutional Selling — 661bps Outflow Over 5 Quarters — FII Institutional Selling — 661bps Outflow Over 5 Quarters Mar 2026 and Jun 2026 shareholding — FII trend reversal to validate re-rating catalyst by the next result.

🚨 What the surface reading misses. The surface reading is: Rapid revenue growth from loss-making early years — high growth rate is catch-up from small profitable base The research reads it further: Company turned profitable at scale only in FY24 (first PAT-positive year Rs40 Cr); the PAT compounding since then (40→107→146 Cr) reflects operating leverage on the distribution fixed cost base plus Medtech mix improvement — this is NOT a cyclical trough recovery but a business model maturation from pre-profit startup to profitable scale player

🚨 What the surface reading misses. The surface reading is: PE at 41x appears expensive for a 4% EBITDA margin business; 25th percentile vs own history still in 'not cheap' territory The research reads it further: The 25th percentile is RELATIVE to this stock's own history — this stock's 10-year median is 54.8x because it commanded a distribution scarcity premium before earnings materialised. The PE has compressed 50% from 82x peak while EPS grew 94.67% — the MULTIPLE is cheap, not the absolute PE level. At 4% EBITDA, a 41x PE on THIN margins that are expanding toward 5% is equivalent to a 30x PE at normalised 5% margins (identical earnings pool).

Lever 2 · Value-added mix — BUILDING. Medtech segment (Anand Chemicells, Ace Cardiopathy, Bio-Med Technology) crossed Rs1,000 Cr annualised; at 15-20% EBITDA vs 4-5% pharma, scaling Medtech toward 20% of revenue is the +100-150bps margin re-rating lever. What proves it keeps working: Medtech Platform — Rs1,000 Cr Platform Crossed, FY27 Margin Delivery Window Open. It stops working if Q1 FY27 EBITDA margin (must be ≥4.5% to confirm FY27 trajectory toward 5%).

Lever 15 · Market-share gains — BUILDING. 100,000+ pharmacies, 3,600 hospitals, 97,500 SKUs from 3,300 manufacturers — organic FY26 like-for-like growth 15.6%, consistently 1.6x industry; the closed-loop system self-reinforces. What proves it keeps working: Pharma Distribution Moat — Organic Growth 1.6x IPM, Two-Way Network Effect. It stops working if Q1 FY27 EBITDA margin (must be ≥4.5% to confirm FY27 trajectory toward 5%).

Lever 7 · Consolidation — BUILDING. FY26 OCF Rs96.2 Cr marks the first cash-positive fiscal year; Q4 generated Rs104.6 Cr alone; FY27 guidance of min 50% EBITDA-to-OCF conversion at Rs400 Cr+ EBITDA implies Rs200 Cr+ OCF target. What proves it keeps working: OCF Inflection — First Positive Fiscal Year in History, FY27 Structural Confirmation. It stops working if Q1 FY27 EBITDA margin (must be ≥4.5% to confirm FY27 trajectory toward 5%).

Lever 14 · A bigger market to sell into — BUILDING. Rs10-12 Cr/month GLP-1 sales at 5% industry value share — disproportionate given portfolio size — secured by full cold-chain coverage at all warehouses when few competitors offer GLP-1 logistics. What proves it keeps working: GLP-1 Cold-Chain Moat — Disproportionate 5% Industry Share via Unique Logistics Capability. It stops working if Q1 FY27 EBITDA margin (must be ≥4.5% to confirm FY27 trajectory toward 5%).

Sources: our stock research file (14 June 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Entero Healthcare Solutions Ltd reported ₹1,940 Cr of revenue in the Jun 26 quarter, +38.2% year on year. That is the 11th straight quarter of year-on-year growth. Over 6 years it has compounded at 30.2% a year. The last full year, FY26, came in at ₹6,591 Cr. The last four reported quarters add to ₹7,128 Cr.

Why this happened. Network expansion Q1→Q4 FY26: pharmacies 71,000→100,000+, warehouses 102→131, SKUs 74,700→97,500, districts 469→523. Two-way moat confirmed per CEO Q1 FY27 call: manufacturers attracted by customer reach, pharmacies attracted by product breadth, creating a closed-loop system. Commercial roles (15% of sales at 2x typical distribution margins) are a margin-accretive within-pharma upgrade. Organic growth guided 23% in FY27 with pharma and Medtech contributing equally.

FY26 revenue came in at ₹6,591 Cr (+29.3% on the year), capping 6 years at 30.2% compound. The latest quarter (Jun 26) printed ₹1,940 Cr, +38.2% year on year — the 11th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +31.8% growth against the decade's 30.2% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +31.9% over the last 4 quarters against +31.5%/yr over the last 8 — stabilising; TTM profit +44.8% vs +76.4%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Entero Healthcare Solutions Ltd's operating margin is 5.0% in the Jun 26 quarter, +1.4 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 0.8% to 4.0%. The current quarter is running above every full year in that window.

Why this happened. FY26 Medtech acquisitions delivered Rs1,000 Cr+ annualised revenue within guided timeline. No further M&A in FY27 H1 creates a clean integration window. Depreciation headwind from IVD reagent rental model (equipment placed at lab sites on 5-year contracts) is non-cash and creates contractual visibility. New Medtech segment expansion targets: imaging, neuropsychiatry, orthopedics. Guided FY27 5% EBITDA margin requires Medtech to contribute its higher-margin commercial economics at scale.

The latest quarter's operating margin is 5.0%, +1.4 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 0.8%–4.0%, and FY26's 4.0% is the top of that band — a record year.

Why the margin moved: operating margin went +1.4 pp year on year while gross margin went +1.5 pp — the gain came mostly from the gross line: input costs and pricing.

Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Entero Healthcare Solutions Ltd earned ₹52.0 Cr of net profit in the Jun 26 quarter, +73.3% year on year. It is the 9th consecutive quarter of growth. Full-year FY26 profit was ₹146 Cr. The 6-year compound rate is 129.5%. That is 2.7% of the quarter's revenue. The same quarter a year earlier earned ₹30.0 Cr.

Jun 26 profit was ₹52.0 Cr, +73.3% year on year — the 9th consecutive quarter of growth. On the full year, FY26 printed ₹146 Cr (+36.4%), and the 6-year compound rate is 129.5%.

Why profit moved: revenue contributed +38.2% and the margin +1.4 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +44.5% vs revenue +31.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −6% of Entero Healthcare Solutions Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹96.0 Cr of operating cash against ₹146 Cr of profit. After ₹444 Cr of capital spending, ₹−348 Cr was left as free cash.

FY26: operating cash of ₹96.0 Cr against reported profit of ₹146 Cr, leaving free cash of ₹−348 Cr after ₹444 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −6% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −6%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: the bigger cash user is investment — capital spending ran 8.0× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Entero Healthcare Solutions Ltd's cash conversion cycle runs 74 days in FY26, down from 82 days in FY21. Capital spending ran ₹791 Cr over the last 3 years. At FY26 sales of ₹6,591 Cr each day of that cycle holds about ₹18.1 Cr, so roughly ₹1,336 Cr sits inside the business at any moment.

FY26: debtors at 67 days, inventory at 52 days — roughly 1.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 74 days, tighter than FY21's 82.

The full loop: cash goes out to suppliers and production on day 0; stock waits 52 days to sell; customers pay about 67 days after that; and suppliers themselves are paid at 45 days — netting out to the 74-day cycle.

In money terms: at FY26 sales of ₹6,591 Cr, each day of the cycle holds about ₹18.1 Cr — so the 74-day loop keeps roughly ₹1,336 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹791 Cr over the last 3 fiscal years against ₹99.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Entero Healthcare Solutions Ltd earns a ROCE of 10% in FY26. That is up from a trough of 1% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 2.2% net margin on 1.83× asset turns.

FY26 ROCE is 10%, recovered from a FY21 trough of 1% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 2.2% net margin × 1.83× asset turns × 2.13× balance-sheet leverage ≈ 8.6% on equity. Margin does its share; leverage is a meaningful part of the equation.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 37% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Entero Healthcare Solutions Ltd carries ₹677 Cr of borrowings against ₹1,689 Cr of equity in FY26, a debt-to-equity of 0.40. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹720 Cr to ₹677 Cr. Capital spending ran ₹791 Cr across the last 3 of those years.

FY26: borrowings of ₹677 Cr against equity of ₹1,689 Cr — a debt-to-equity of 0.40. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹720 Cr to ₹677 Cr while capital spending ran ₹791 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 37% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions cut 19.0 points of Entero Healthcare Solutions Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 4.4% of the company. Domestic institutions moved +13.4 points over the same window, to 15.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: −19.0 points over 8 quarters to 4.4%; Domestic institutions: +13.4 points over 8 quarters to 15.5%; Promoters: +0.0 points over 8 quarters to 52.4%.

Why the register moved: rotation — foreign institutions −19.0 points against domestic institutions +13.4 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Entero Healthcare Solutions Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Entero Healthcare Solutions Ltd trades at 47.8× P/E, mid-range by its own standards (46th percentile). Its long-run median P/E is 50.8×, measured across 2.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 47.8× is mid-range by its own standards (46th percentile), against a long-run median of 50.8× measured over 2.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.

Why the multiple sits where it does: over the past year annual EPS moved +21.3% against a +17.4% price move — earnings outran the price, pushing the multiple DOWN its own range.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 37% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Entero Healthcare Solutions Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +581.8% at its peak to +44.8% but is still expanding, ROCE lifting at 10.0%. The read is built from 8 quarters across 4 curves, on partial evidence.

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

66.2/100 — rank 1 of 4 in Pharmacy Distribution · 72% evidence confidence

Entero Healthcare Solutions Ltd scores 66.2 out of 100 against the 4 companies it is compared with in Pharmacy Distribution, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 27.9 + 8.3 + 10 + 20 = 66.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Entero Healthcare Solutions Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

GLP-1 Stated Market Share Halved · 26 May 2026. In the Feb 2026 call, management claimed they were capturing almost 10% of the GLP drug market due to their pan-India presence and unique value proposition. However, in the May 2026 call, they stated they are capturing only about 5% of the overall industry value for GLP drugs, halving their claimed market share without explaining the sudden apparent drop.

MedTech Acquisition Count Discrepancy · 26 May 2026. In the Feb 2026 call, management explicitly named four acquisitions closed within the MedTech segment for the year. However, in the May 2026 earnings call, management summarized the full-year M&A activity by stating they closed only three acquisitions in the MedTech segment, altering some entity names and completely dropping one from the MedTech tally.

🚨 EBITDA Margin Target Delay · 13 February 2026. In the November 2025 call, management explicitly guided that the EBITDA margin should rise to a range of 4.5% to 4.75% once the high-margin Medtech acquisitions were integrated in the second half of the year. However, in the February 2026 call, the company reported a Q3 EBITDA margin of 4.0%, failing to show any sequential expansion from Q2 levels despite confirming the closure of multiple Medtech deals during the period. Earlier call (Nov 2025): “if we were at Q2 at 4%, then post closing of these deals, we should be between 4.5% to 4.75%. That’s my estimate as of now based on what financials they had before we acquired them.” Later call (Feb 2026): “EBITDA for the quarter was 68 crores, representing a growth of 36% year-over-year with margins improving by around 30 bps versus last year to 4%.”

Growth Benchmark Narrative Shift · 13 February 2026. During the November 2025 call, management emphasized their outperformance relative to the Indian Pharmaceutical Market (IPM) growth rate (1.8x) as a critical indicator of their organic success. Contrastingly, in the February 2026 call, when the outperformance ratio narrowed to 1.4x, management dismissed the validity of the metric, instructing analysts to ignore the quarterly calculation due to industry volatility. Earlier call (Nov 2025): “organic growth was 13.4% year-on-year, which is approximately 1.8x the IPM growth rate of 7.3% during the same period.” Later call (Feb 2026): “I would say ignore this quarterly metric. I was surprised to see 12% growth on the IPM side because it has been 7-8% for the last several quarters. The denominator completely changed, so I wouldn’t read much into it.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions